Group 1 - ALK will publish its annual report for 2025 on February 20, 2026, and will host a presentation for investors and analysts later that day at 1:30 p.m. CET [1] - The presentation will be led by ALK's management team, including Peter Halling (President & CEO), Claus Steensen Sølje (CFO), and Per Plotnikof (VP, Head of IR) [1] - The meeting will be available as a live audio webcast and can be replayed on ALK's website [2] Group 2 - Participants can join the conference call by registering through a provided link, and they will receive dial-in details via email [3] - The presentation materials will be accessible on ALK's website shortly before the meeting begins [4] Group 3 - ALK is a global specialty pharmaceutical company focused on allergy, involved in the entire value chain from development to marketing of products for respiratory allergies and anaphylaxis [6] - The company is headquartered in Denmark, employs around 2,700 people, and is listed on Nasdaq Copenhagen [6]

Core Insights - Regeneron Pharmaceuticals is set to present 36 abstracts at the 2026 AAAAI Annual Meeting, highlighting new Phase 3 data for investigational allergen-blocking antibodies targeting cat and birch allergies, as well as new insights on Dupixent's efficacy across various diseases [1][2] Regeneron's Pipeline and Research - The company is pioneering first-in-class treatments for cat and birch allergies, with Phase 3 data demonstrating the potential to alleviate ocular symptoms in adults [2][3] - Additional registration-enabling trials for these allergy treatments are planned for this year, aiming to evaluate similar endpoints over longer follow-up periods [3] - Regeneron's broader allergy pipeline includes innovative strategies aimed at eliminating all IgE-mediated allergies [3] Dupixent Insights - New analyses on Dupixent will be presented, focusing on its impact on allergy sensitization in children with atopic dermatitis, measuring IgE levels for various allergens over a treatment period of up to 1.5 years [4] - Real-world analyses will assess the potential benefits of initiating Dupixent earlier in asthma treatment, comparing its effects on exacerbation rates and corticosteroid use against other treatment options [5] - Late-breaking data from the Phase 3 AIMS trial for allergic fungal rhinosinusitis (AFRS) will also be shared, which supports a supplemental Biologics License Application currently under Priority Review [6] Presentation Details - The full list of Regeneron's presentations at the AAAAI includes various studies on allergic inflammation, immunological evaluations, and the efficacy of antibody cocktails in treating allergic conditions [7][8]

Core Viewpoint - ALK has received a positive opinion from the CHMP recommending the marketing authorisation for EURneffy, a 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older [1][2][3] Group 1: Product Development and Authorisation - The positive CHMP opinion supports an extension to the existing marketing authorisation for EURneffy 2 mg, which was granted in August 2024 for adults and children weighing ≥30 kg [2] - The marketing authorisation for EURneffy 1 mg, if approved, will be valid across all EU member states, as well as Iceland, Liechtenstein, and Norway [3] Group 2: Market Context and Impact - Anaphylaxis is a severe allergic reaction requiring immediate medical intervention, with an incidence rate of approximately 1 in 761 children in Europe each year [4] - Foods are the most common trigger for anaphylaxis in children, accounting for over two-thirds of cases, with increasing hospitalisations due to food allergies [4] Group 3: Strategic Partnerships - ALK entered into a strategic license agreement with ARS Pharmaceuticals in November 2024, granting exclusive global rights to commercialise neffy, excluding the USA, Australia, New Zealand, Japan, and China [5] - The partnership was extended in May 2025 to include a co-promotion agreement in the USA [5] Group 4: Company Overview - ALK is a global specialty pharmaceutical company focused on allergy, covering the entire value chain from development to marketing of products for diagnosing and treating respiratory allergies and severe allergic reactions [8] - The company is headquartered in Denmark and employs around 2,700 people worldwide, listed on Nasdaq Copenhagen [8]

Group 1 - ALK will publish its results for the first nine months (Q3) of 2025 on 13 November 2025 [1] - An investor and analyst presentation will be held on the same day at 1:30 p.m. CET, featuring comments on the results and future outlook [1] - Key representatives from ALK during the presentation will include Peter Halling (President & CEO), Claus Steensen Sølje (CFO), and Per Plotnikof (VP, Head of IR) [1] Group 2 - The meeting will be available as a live audio webcast and can be replayed on ALK's website [2] - Participants can join the conference call by registering through a provided link, receiving dial-in details via email [3] - The presentation materials will be accessible on ALK's website shortly before the meeting begins [4] Group 3 - ALK-Abelló A/S is a global specialty pharmaceutical company focused on allergy and allergic asthma treatments [6] - The company markets allergy immunotherapy treatments and other related products and services [6] - ALK is headquartered in Hørsholm, Denmark, employs around 2,800 people globally, and is listed on Nasdaq Copenhagen [6]

Neffy Approval and Indication - Neffy (epinephrine nasal spray) has been approved for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing ≥30kg[4, 65] - The available dose strength is a 2 mg nasal spray device[8] - A supplemental regulatory application (sNDA) for a 1 mg dose for children 15 kg to <30 kg is expected to be filed with the FDA in Q3 2024[2, 22] Addressing Unmet Needs and Market Opportunity - Only 10%-20% of patients with active prescriptions use them as indicated, highlighting significant limitations with current treatment options[5] - Approximately 40 million patients have type 1 allergic reactions, with ~20 million diagnosed and under physician care[25] - The US severe allergic reaction market has shown consistent growth, with a +6.5% Compound Annual Growth Rate (CAGR) since 2010 and +12.7% Year-over-Year (YoY) growth in 2023[25] - Market research indicates a 45% reduction in time to use with neffy compared to current devices, suggesting faster administration[30] Clinical Trial Data and Safety - Registrational studies demonstrate comparable pharmacodynamic (PD) surrogates for efficacy and pharmacokinetic (PK) with approved products[19] - In clinical trials, 100% of patients responded to a single dose of neffy within the first 15 minutes, and did not require a second dose of epinephrine per treatment guidelines in an oral food challenge induced anaphylaxis study[41] - The most common adverse events (>2%) with a single dose of neffy were mild nasal discomfort (9.7%) and mild headache (6%)[12, 19] Commercialization and Market Access - A commercial force of 110 sales representatives and area sales managers will target 12,500 allergy specialists and high decile prescribers[38] - The company anticipates at least 80% unrestricted access in the US by mid-2025[62] - A co-pay buy-down program will reduce the patient co-pay to $25 for commercially insured patients[48, 49] Global Expansion and Future Development - Filings by partners in Australia, China, and Japan are expected in 2024, with filings planned in Canada and other regions[22, 62] - Phase 2b trial results for treating acute urticaria exacerbations in CSU patients on antihistamine therapy are expected in 2025[23, 62] - The company has a strong balance sheet of $218.7 million and an expected operating runway of at least 3 years to support US commercialization[62]

Core Viewpoint - ARS Pharmaceuticals has entered into a co-promotion agreement with ALK-Abelló A/S to promote neffy, an epinephrine nasal spray, targeting pediatricians and enhancing access to this needle-free treatment for severe allergic reactions, particularly ahead of the back-to-school season [1][2][3] Company Overview - ARS Pharmaceuticals is focused on empowering at-risk patients and caregivers to protect against severe allergic reactions that could lead to anaphylaxis [1][17] - The company is commercializing neffy, the only approved needle-free treatment for Type I allergic reactions, including anaphylaxis, for patients aged 4 years and older who weigh at least 33 pounds [4][6][17] Partnership Details - The agreement allows ARS Pharma to recognize all U.S. revenue and maintain sole responsibility for U.S. commercialization activities, including marketing and distribution [2][5] - ALK will promote neffy to approximately 9,000 pediatricians, representing about 55% of all community-use epinephrine prescriptions in the U.S. [2][5] - The partnership includes performance-based payments for ALK based on exceeding specific market share thresholds, starting at 30% of net revenue above an initial threshold in the second year [5] Market Strategy - ARS Pharma plans to launch a direct-to-consumer campaign in May 2025, coinciding with the availability of a 1 mg dose for children over four years old [3] - The company anticipates broadening unrestricted commercial access for neffy over the summer, ensuring a smooth prescribing experience for patients and physicians [3] Financial Outlook - ARS Pharma expects its operating expenses to increase by approximately $3 million per quarter starting in Q3 2025, but this will not impact its cash flow for 2025 [3]